Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.625 USD | -2.34% |
|
+1.41% | -31.83% |
Jun. 03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
May. 30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
Financials (USD)
Sales 2024 * | 28.88M | Sales 2025 * | 43.41M | Capitalization | 156M |
---|---|---|---|---|---|
Net income 2024 * | -46M | Net income 2025 * | -44M | EV / Sales 2024 * | 5.42 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.6 x |
P/E ratio 2024 * |
-3.23
x | P/E ratio 2025 * |
-4.42
x | Employees | 101 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.5% |
Latest transcript on TriSalus Life Sciences, Inc.
1 day | -2.69% | ||
1 week | +1.41% | ||
Current month | -19.55% | ||
1 month | -23.81% | ||
3 months | -38.98% | ||
6 months | -39.50% | ||
Current year | -31.83% |
![Extreme 5.5101](/images/extremecours_fleche.png)
![Extreme 5.5101](/images/extremecours_fleche.png)
![Extreme 5.5101](/images/extremecours_fleche.png)
![Extreme 3.32](/images/extremecours_fleche.png)
![Extreme 3.32](/images/extremecours_fleche.png)
![Extreme 3.32](/images/extremecours_fleche.png)
![Extreme 3.32](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Mary Szela
CEO | Chief Executive Officer | 60 | 17-12-31 |
Sean Murphy
DFI | Director of Finance/CFO | 71 | 23-08-09 |
Steven Katz
CTO | Chief Tech/Sci/R&D Officer | 49 | 23-08-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kerry Hicks
BRD | Director/Board Member | 64 | 23-08-09 |
Mats Wahlström
CHM | Chairman | 70 | 23-08-09 |
George Martin
BRD | Director/Board Member | 65 | 23-08-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-26 | 5.76 | +1.95% | 16 778 |
24-06-26 | 5.65 | +1.44% | 24,262 |
24-06-25 | 5.57 | -4.30% | 30,609 |
24-06-24 | 5.82 | +2.28% | 33,364 |
24-06-21 | 5.69 | +0.18% | 33,531 |
End-of-day quote Nasdaq, June 26, 2024
More quotes![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.83% | 156M | |
+16.08% | 122B | |
+19.80% | 113B | |
+18.95% | 26.49B | |
-24.12% | 19.4B | |
-19.03% | 16.24B | |
-20.89% | 15.4B | |
-46.14% | 15.15B | |
+63.69% | 14.93B | |
+4.36% | 13.52B |
- Stock Market
- Equities
- TLSI Stock